0 CHECKOUT

TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update

  • ID: 1537342
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

The TGF-beta receptor signaling pathway activates the MAPK/SMAD signaling modules.

There are today 396 companies plus partners developing 509 TGF-beta receptor pathway targeting drugs in 1845 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 265 drugs. Tgf-Beta Receptor Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 259 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 252 out of the 255 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 54 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug Pipeline Update at a Glance

Investigators
Includes more than 396 principal READ MORE >

Note: Product cover images may vary from those shown
2 of 2



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
3 of 2
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)